Hansoh Pharmaceutical Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Huijuan Zhong
Chief executive officer
CN¥14.8m
Total compensation
| CEO salary percentage | 49.6% |
| CEO tenure | 8.9yrs |
| CEO ownership | n/a |
| Management average tenure | 8.7yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?
Nov 04
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥5b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥3b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
Compensation vs Market: Huijuan's total compensation ($USD2.04M) is above average for companies of similar size in the Hong Kong market ($USD906.49K).
Compensation vs Earnings: Huijuan's compensation has increased by more than 20% in the past year.
CEO
Huijuan Zhong (63 yo)
8.9yrs
Tenure
CN¥14,807,000
Compensation
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 8.9yrs | CN¥14.81m | no data | |
| Executive Director | 8.7yrs | CN¥9.39m | 0.023% HK$ 25.3m | |
| Executive Director | 8.9yrs | CN¥16.63m | 0.021% HK$ 22.8m | |
| VP & CFO | no data | no data | no data | |
| Chief of Science Officer | 2.6yrs | no data | no data | |
| Senior Vice President | 15.7yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Joint Company Secretary & Senior VP | 6.3yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
8.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: 3692's management team is seasoned and experienced (8.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairlady | 8.9yrs | CN¥14.81m | no data | |
| Executive Director | 8.7yrs | CN¥9.39m | 0.023% HK$ 25.3m | |
| Executive Director | 8.9yrs | CN¥16.63m | 0.021% HK$ 22.8m | |
| Independent Non-Executive Director | 5.5yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.5yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.5yrs | CN¥360.00k | no data |
7.1yrs
Average Tenure
65yo
Average Age
Experienced Board: 3692's board of directors are considered experienced (7.1 years average tenure).